60 Degrees Pharmaceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio
60 Degrees Pharmaceuticals, Inc. Common Stock cash flow-to-debt ratio. 60 Degrees Pharmaceuticals, Inc. Common Stock (SXTP) has a Cash Flow-to-Debt Ratio of -1.27x as of June 2026, meaning its operating cash flow of $-2.23 Million could theoretically repay -1% of its total liabilities ($1.75 Million) in one year. Check SXTP cash flow quality index to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of 60 Degrees Pharmaceuticals, Inc. Common Stock (2020–2025)
Cash flow-to-debt ratio of 60 Degrees Pharmaceuticals, Inc. Common Stock from 2020 to 2025. Historical debt coverage capacity for 60 Degrees Pharmaceuticals, Inc. Common Stock across 6 annual periods. Also explore 60 Degrees Pharmaceuticals, Inc. Common (SXTP) equity growth momentum to track the company's year-over-year net asset growth rate.
60 Degrees Pharmaceuticals, Inc. Common Stock Cash Flow-to-Debt Ratio by Year (2020–2025)
60 Degrees Pharmaceuticals, Inc. Common Stock cash flow-to-debt ratio by year from 2020 to 2025. Year-by-year debt coverage analysis for 60 Degrees Pharmaceuticals, Inc. Common Stock. For the full cash flow conversion analysis, see how efficiently does 60 Degrees Pharmaceuticals, Inc. Common generate cash.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.45x | $-6.85 Million | $1.99 Million | ▼ -10.1% |
| 2024 | -3.13x | $-5.65 Million | $1.80 Million | ▼ -105.7% |
| 2023 | -1.52x | $-4.54 Million | $2.99 Million | ▼ -3733.6% |
| 2022 | -0.04x | $-1.01 Million | $25.45 Million | ▼ -19.5% |
| 2021 | -0.03x | $-649.11K | $19.55 Million | ▼ -310.4% |
| 2020 | -0.01x | $-167.30K | $20.68 Million | — |